170 related articles for article (PubMed ID: 30949937)
1. Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [
Chiaravalloti A; Esposito V; Ursini F; Di Giorgio E; Zinzi M; Calabria F; Cimini A; Schillaci O
Ann Nucl Med; 2019 Jul; 33(7):471-480. PubMed ID: 30949937
[TBL] [Abstract][Full Text] [Related]
2.
Patel CB; Fazzari E; Chakhoyan A; Yao J; Raymond C; Nguyen H; Manoukian J; Nguyen N; Pope W; Cloughesy TF; Nghiemphu PL; Czernin J; Lai A; Ellingson BM
J Neurooncol; 2018 Sep; 139(2):399-409. PubMed ID: 29679199
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting ¹⁸F FDOPA standardized uptake value in patients with primary brain tumors after treatment.
Chiaravalloti A; Fiorentini A; Villani V; Carapella C; Pace A; Di Pietro B; Di Russo C; Palumbo B; Floris R; Schillaci O
Nucl Med Biol; 2015 Apr; 42(4):355-9. PubMed ID: 25624151
[TBL] [Abstract][Full Text] [Related]
4. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
5. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
[TBL] [Abstract][Full Text] [Related]
6. Identify glioma recurrence and treatment effects with triple-tracer PET/CT.
Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z
BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015
[TBL] [Abstract][Full Text] [Related]
7. High Tumor Uptake on
De Rycke O; Perrier M; Ouvrard É; Mennetrey C; Lachachi C; Bando-Delaunay A; Morland D; Goichot B; Taieb D; Walter T; Cadiot G; Cros J; Hentic O; Ruszniewski P; Lebtahi R; Imperiale A; de Mestier L
J Nucl Med; 2023 Nov; 64(11):1699-1705. PubMed ID: 37652547
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
9. IDH mutation is paradoxically associated with higher
Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Karunanithi S; Bandopadhyaya GP; Sharma P; Kumar A; Singla S; Malhotra A; Gupta DK; Bal C
Clin Nucl Med; 2014 Feb; 39(2):e121-8. PubMed ID: 23579970
[TBL] [Abstract][Full Text] [Related]
11. A high
Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
[TBL] [Abstract][Full Text] [Related]
12. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.
Schwarzenberg J; Czernin J; Cloughesy TF; Ellingson BM; Pope WB; Grogan T; Elashoff D; Geist C; Silverman DH; Phelps ME; Chen W
Clin Cancer Res; 2014 Jul; 20(13):3550-9. PubMed ID: 24687922
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
14. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.
Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM
Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233
[TBL] [Abstract][Full Text] [Related]
15. Adrenal tracer uptake by
Noordzij W; Glaudemans AWJM; Schaafsma M; van der Horst-Schrivers ANA; Slart RHJA; van Beek AP; Kerstens MN
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1560-1566. PubMed ID: 31011769
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of O-(2-[
Kertels O; Kessler AF; Mihovilovic MI; Stolzenburg A; Linsenmann T; Samnick S; Brändlein S; Monoranu CM; Ernestus RI; Buck AK; Löhr M; Lapa C
Mol Imaging Biol; 2019 Dec; 21(6):1174-1181. PubMed ID: 30977078
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Tripathi M; Sharma R; D'Souza M; Jaimini A; Panwar P; Varshney R; Datta A; Kumar N; Garg G; Singh D; Grover RK; Mishra AK; Mondal A
Clin Nucl Med; 2009 Dec; 34(12):878-83. PubMed ID: 20139821
[TBL] [Abstract][Full Text] [Related]
18. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and grading accuracy of
Xiao J; Jin Y; Nie J; Chen F; Ma X
BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
